Daewoong Pharmaceutical is partnering with affiliates Daewoong Therapeutics and Daewoong Bio to develop two drug delivery technologies aimed at expanding administration options for therapeutics, including biologics and antibody-drug conjugates. The platforms are Thermicra, a high-concentration subcutaneous injection formulation, and CLOPAM, a dissolvable microneedle delivery system.
Thermicra is designed to enable subcutaneous formulations at concentrations of at least 400 mg/mL without hyaluronidase, addressing challenges associated with intravenous administration. This technology could reduce administration time and simplify treatment procedures.
CLOPAM uses dissolvable microneedles in a skin-applied patch to deliver active pharmaceutical ingredients. The companies are assessing its potential for small molecules and peptide therapies. Daewoong is also investing in manufacturing infrastructure, with a Thermicra facility expected to be completed by December 2027 and a GMP-approved facility for CLOPAM planned for the first half of 2027.
Source: drug-dev.com · Image: Nanoparticles in Brain Metastases (26155288848) by NIH Image Gallery from Bethesda, Maryland, USA, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
